Source: Health Products and Food Branch (CA) Revision Year: 2018
EMEND IV – Fosaprepitant for injection.
150 mg fosaprepitant /vial (as fosaprepitant dimeglumine).
| Route of Administration | Dosage Form/Strength | Non-Medicinal Ingredients |
|---|---|---|
| Intravenous | Lyophilized powder/150 mg/vial | Edetate disodium, polysorbate 80, lactose anhydrous, sodium hydroxide and/or hydrochloric acid. |
EMEND IV is available as a 150 mg single dose per 10 mL glass vial as a white to off-white lyophilized solid to be administered intravenously as an infusion, upon reconstitution and dilution. One vial per carton.
Active ingredients: Each vial of EMEND IV 150 mg for intravenous administration contains 245.3 mg of fosaprepitant dimeglumine equivalent to 150 mg of fosaprepitant free acid.
Inactive ingredients: Each vial of EMEND IV for intravenous administration contains the following inactive ingredients: edetate disodium, polysorbate 80, lactose anhydrous, sodium hydroxide and/or hydrochloric acid (for pH adjustment).
| Marketing Informations | Authorization Dates |
|---|---|
|
Authorization holder:
Merck Canada Inc., 16750 route Transcanadienne, Kirkland, QC Canada H9H 4M7, www.merck.ca 218162 |
Date of revision:
October 17, 2018 |
| Drug | Countries | |
|---|---|---|
| EMEND IV | Australia, Brazil, Canada, Hong Kong, Mexico, Singapore |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
